These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 15257626)
1. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Hashim H; Abrams P Drugs; 2004; 64(15):1643-56. PubMed ID: 15257626 [TBL] [Abstract][Full Text] [Related]
2. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Brunton S; Kuritzky L Curr Med Res Opin; 2005 Jan; 21(1):71-80. PubMed ID: 15881477 [TBL] [Abstract][Full Text] [Related]
3. Solifenacin in the management of the overactive bladder syndrome. Robinson D; Cardozo L Int J Clin Pract; 2005 Oct; 59(10):1229-36. PubMed ID: 16178992 [TBL] [Abstract][Full Text] [Related]
4. Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies. Hegde SS; Mammen M; Jasper JR Curr Opin Investig Drugs; 2004 Jan; 5(1):40-9. PubMed ID: 14983972 [TBL] [Abstract][Full Text] [Related]
5. Overactive bladder in the elderly: a guide to pharmacological management. Staskin DR Drugs Aging; 2005; 22(12):1013-28. PubMed ID: 16363885 [TBL] [Abstract][Full Text] [Related]
6. Muscarinic receptor subtypes and management of the overactive bladder. Chapple CR; Yamanishi T; Chess-Williams R Urology; 2002 Nov; 60(5 Suppl 1):82-8; discussion 88-9. PubMed ID: 12493364 [TBL] [Abstract][Full Text] [Related]
7. [Changes in muscarinic receptors of the aging bladder]. Andersson KE; Schröder A Urologe A; 2004 May; 43(5):552-6. PubMed ID: 15098089 [TBL] [Abstract][Full Text] [Related]
8. Darifenacin in the treatment of overactive bladder. Parsons M; Robinson D; Cardozo L Int J Clin Pract; 2005 Jul; 59(7):831-8. PubMed ID: 15963212 [TBL] [Abstract][Full Text] [Related]
12. Muscarinic receptors in the bladder: from basic research to therapeutics. Hegde SS Br J Pharmacol; 2006 Feb; 147 Suppl 2(Suppl 2):S80-7. PubMed ID: 16465186 [TBL] [Abstract][Full Text] [Related]
13. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. Garely AD; Burrows L Drug Saf; 2004; 27(13):1043-57. PubMed ID: 15471509 [TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. Cardozo L; Thorpe A; Warner J; Sidhu M BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203 [TBL] [Abstract][Full Text] [Related]
15. Management of OAB in those over age 65. Natalin R; Lorenzetti F; Dambros M Curr Urol Rep; 2013 Oct; 14(5):379-85. PubMed ID: 23922134 [TBL] [Abstract][Full Text] [Related]
16. The pharmacotherapy of overactive bladder. Athanasopoulos A Expert Opin Pharmacother; 2011 May; 12(7):1003-5. PubMed ID: 21291348 [TBL] [Abstract][Full Text] [Related]
18. Diagnosis and treatment of the overactive bladder. Wein AJ Urology; 2003 Nov; 62(5 Suppl 2):20-7. PubMed ID: 14662403 [TBL] [Abstract][Full Text] [Related]
19. Overactive bladder treatments in early phase clinical trials. Colli E; Digesu GA; Olivieri L Expert Opin Investig Drugs; 2007 Jul; 16(7):999-1007. PubMed ID: 17594185 [TBL] [Abstract][Full Text] [Related]
20. Role of muscarinic receptor antagonists in urgency and nocturia. Michel MC; de la Rosette JJ BJU Int; 2005 Sep; 96 Suppl 1():37-42. PubMed ID: 16083453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]